Protection of the Human Gut Microbiome From Antibiotics

Study information

Needs review

study design

randomized controlled trial

Citation

PMID PubMed identifier for scientific articles.

29186529

DOI Digital object identifier for electronic documents.

10.1093/infdis/jix604

URI

Authors

de Gunzburg J, Ghozlane A, Ducher A, Le Chatelier E, Duval X, Ruppé E, Armand-Lefevre L, Sablier-Gallis F, Burdet C, Alavoine L, Chachaty E, Augustin V, Varastet M, Levenez F, Kennedy S, Pons N, Mentré F, Andremont A

Journal

The Journal of infectious diseases

Year

2018

Keywords:

Clostridium difficile, antibiotics, fluoroquinolones, microbiome

Background: Antibiotics are life-saving drugs but severely affect the gut microbiome with short-term consequences including diarrhea and selection of antibiotic-resistant bacteria. Long-term links to allergy and obesity are also suggested. We devised a product, DAV132, and previously showed its ability to deliver a powerful adsorbent, activated charcoal, in the late ileum of human volunteers. Methods: We performed a randomized controlled trial in 28 human volunteers treated with a 5-day clinical regimen of the fluoroquinolone antibiotic moxifloxacin in 2 parallel groups, with or without DAV132 coadministration. Two control goups of 8 volunteers each receiving DAV132 alone, or a nonactive substitute, were added. Results: The coadministration of DAV132 decreased free moxifloxacin fecal concentrations by 99%, while plasmatic levels were unaffected. Shotgun quantitative metagenomics showed that the richness and composition of the intestinal microbiota were largely preserved in subjects co-treated with DAV132 in addition to moxifloxacin. No adverse effect was observed. In addition, DAV132 efficiently adsorbed a wide range of clinically relevant antibiotics ex vivo. Conclusions: DAV132 was highly effective to protect the gut microbiome of moxifloxacin-treated healthy volunteers and may constitute a clinical breakthrough by preventing adverse health consequences of a wide range of antibiotic treatments. Clinical Trials Registration: NCT02176005.

Experiment 1

Edit History Delete

Flag for review

Your review change was submittedDuplicate this Experiment Add a new Signature

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-1-11

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): WikiWorks, ChiomaBlessing

Subjects

Location of subjects: France

Host species Species from which microbiome was sampled. Contact us to have more species added.: Homo sapiens

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology: Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology: Antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent

Group 0 name Corresponds to the control (unexposed) group for case-control studies: Negative control group (CLT)

Group 1 name Corresponds to the case (exposed) group for case-control studies: moxifloxacin treated group (MXF)

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: healthy male and female volunteers aged >18 years

Group 0 sample size Number of subjects in the control (unexposed) group: 8

Group 1 sample size Number of subjects in the case (exposed) group: 14

Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any): 3 months

Lab analysis

Sequencing type: WMS

16S variable region One or more hypervariable region(s) of the bacterial 16S gene: Not specified

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance: Mass spectrometry

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).: relative abundances

Statistical test: Mann-Whitney (Wilcoxon)

Significance threshold p-value or FDR threshold used for differential abundance testing (if any): 0.05

MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?: Yes

Alpha Diversity

Richness Number of species: decreased

Signature 1

Edit History Delete

Mark reviewed

Your review change was submitted

Needs review

Curated date: 2021/01/10

Curator: Mst Afroza Parvin

Revision editor(s): WikiWorks

Source: Supplementary table 3, Supplementary figure 1

Description: A detailed analysis of the MGSs that differed significantly between treatment groups

Abundance in Group 1: increased abundance in moxifloxacin treated group (MXF)

NCBI	Quality Control	Links
Archaea
Blautia

Revision editor(s): WikiWorks

Signature 2

Edit History Delete

Mark reviewed

Your review change was submitted

Needs review

Curated date: 2021/01/10

Curator: Mst Afroza Parvin

Revision editor(s): Lwaldron, WikiWorks

Source: Supplementary table 3, Supplementary figure 1

Description: A detailed analysis of the MGSs that differed significantly between treatment groups

Abundance in Group 1: decreased abundance in moxifloxacin treated group (MXF)

NCBI	Quality Control	Links
Alistipes
Alistipes finegoldii
Alistipes onderdonkii
Alistipes putredinis
Alistipes shahii
Bacteroidales
Barnesiella intestinihominis
Bifidobacterium adolescentis
Bifidobacterium pseudocatenulatum
Bilophila wadsworthia
Blautia
Blautia sp.
Butyricimonas
Butyricimonas virosa
Catenibacterium
Cloacibacterium sp.
Clostridium
Clostridium sp.
Coprobacillus
Dorea formicigenerans
Eubacteriales
Eubacterium
Faecalibacterium
Faecalibacterium prausnitzii
Bacillota
Haemophilus parainfluenzae
Intestinibacter bartlettii
Lachnospira eligens
Lachnospiraceae
Odoribacter splanchnicus
Oscillibacter
Oscillibacter sp.
Oscillospiraceae
Parabacteroides distasonis
Parasutterella excrementihominis
Roseburia inulinivorans
Ruminococcus callidus
Streptococcus parasanguinis

Revision editor(s): Lwaldron, WikiWorks

Experiment 2

Edit History Delete

Mark reviewed

Your review change was submittedDuplicate this Experiment Add a new Signature

Needs review

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): WikiWorks, Victoria

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies: moxifloxacin treated group (MXF)

Group 1 name Corresponds to the case (exposed) group for case-control studies: DAV132+moxifloxacin treated group (MXF+DAV132)

Group 0 sample size Number of subjects in the control (unexposed) group: 14

Lab analysis

Statistical Analysis

Alpha Diversity

Richness Number of species: increased

Signature 1

Edit History Delete

Mark reviewed

Your review change was submitted

Needs review

Curated date: 2021/01/10

Curator: Mst Afroza Parvin

Revision editor(s): WikiWorks

Source: Supplementary table 3, Supplementary figure 1

Description: A detailed analysis of the MGSs that differed significantly between treatment groups

Abundance in Group 1: increased abundance in DAV132+moxifloxacin treated group (MXF+DAV132)

NCBI	Quality Control	Links
Parabacteroides distasonis
Bilophila wadsworthia
Roseburia inulinivorans
Odoribacter splanchnicus
Lachnospiraceae
Blautia sp.
Clostridium sp.
Bacillota
Faecalibacterium prausnitzii
Ruminococcus callidus
Alistipes shahii
Alistipes
Faecalibacterium
Parasutterella excrementihominis
Cloacibacterium sp.
Bifidobacterium adolescentis
Alistipes onderdonkii
Blautia
Oscillibacter
Oscillibacter sp.
Coprobacillus
Alistipes finegoldii
Butyricimonas virosa
Oscillospiraceae
Eubacteriales
Eubacterium
Alistipes putredinis
Butyricimonas
Barnesiella intestinihominis
Lachnospira eligens
Catenibacterium
Dorea formicigenerans
Haemophilus parainfluenzae
Alistipes senegalensis